Johnson & Johnson (NYSE:JNJ) Wells Fargo 2024 Healthcare Conference September 5, 2024 11:00 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech Jessica Moore - Vice President of Investor Relations Tracy Menkowski - Senior Director of Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen Barry, we're ready? All right, good morning. Welcome back. I am Larry Biegelsen, the Medical Device Analyst at Wells Fargo. And it's my plea ...

Johnson & Johnson (NYSE:JNJ) Wells Fargo 2024 Healthcare Conference September 5, 2024 11:00 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech Jessica Moore - Vice President of Investor Relations Tracy Menkowski - Senior Director of Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen Barry, we're ready? All right, good morning. Welcome back. I am Larry Biegelsen, the Medical Device Analyst at Wells Fargo. And it's my plea ...

Johnson & Johnson and Altria Group are two prominent dividend stocks, but I wouldn't rely on their payouts.Investing in dividend stocks can seem like a great way to pad your portfolio's returns, especially when you're investing in dividend growth stocks that increase their payments over the years. The risk, however, is that investors often look at a stock's track record for paying dividends, and use that as a justification for why it may be a safe income investment to hold for the long term. But the past do ...

Johnson & Johnson (NYSE:JNJ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 10:45 AM ET Company Participants Joaquin Duato - CEO & Chairman John Reed - Head of Pharma R&D Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. All right. Thanks for joining us, everybody. I'm Terence Flynn, the U.S. large cap biopharma analyst. Very pleased to be hosting Johnson & Johnson this morning. For important disclosures, please see the Morgan Stanley Research discl ...

Johnson & Johnson (NYSE:JNJ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 10:45 AM ET Company Participants Joaquin Duato - CEO & Chairman John Reed - Head of Pharma R&D Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. All right. Thanks for joining us, everybody. I'm Terence Flynn, the U.S. large cap biopharma analyst. Very pleased to be hosting Johnson & Johnson this morning. For important disclosures, please see the Morgan Stanley Research discl ...

Johnson & Johnson (JNJ) submitted abiologics license application (BLA) to the FDA seeking approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in generalized myasthenia gravis (gMG) indication.The FDA filing is supported by data from the phase III Vivacity-MG3 study, which evaluated nipocalimab in adults with gMG, including those with anti-AChR, anti-MuSK and anti-LRP4 positive antibodies. Data from the study showed that patients who received nipocalimab plus standard of care ( ...

In addition to profiting from ordinary trading activities, the stock market offers opportunities for investors seeking passive income through dividend payouts. Notably, some stocks are set up to reward shareholders regularly. As the markets look ahead to 2025, several stocks can be tapped to offer passive income. Some of these companies have a history of stable dividends and consistent growth.Therefore, below are three stocks to consider for a dividend-focused portfolio in 2025. Johnson & Johnson (NYSE: JNJ ...

CHINA - 2024/07/27: In this photo illustration, Johnson & Johnson logo is displayed on a smartphone ... [+] with a laptop keyboard background. (Photo Illustration by Serene Lee/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIf you are a Johnson & Johnson investor and have been enjoying the stock’s steady dividends, it may be time to look elsewhere. As of this moment, we find DaVita - a healthcare company focused on kidney dialysis services - and Duke Energy - an electric an ...

Johnson & Johnson JNJ has just made a significant technical move, achieving a Golden Cross. This technical pattern occurs when a stock’s short-term moving average crosses above its long-term moving average, indicating a potential shift from a bearish to a bullish trend. Chart created using Benzinga ProFor Johnson & Johnson, the stock’s 50-day simple moving average (SMA) of $155.36 has crossed above the 200-day SMA of $154.46, signaling strong upward momentum.Golden Cross: What It Means For Johnson & Johnson ...

Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies  Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study results in the class demonstrating sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+SPRING HOUSE, Pa., Aug. 29, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a Biolog ...